22.418 articles found

Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.

Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M.

Eur J Intern Med · 2007-11-28

DOI: 10.1016/j.ejim.2007.10.003PMID: 18549943

Treatment with combined use of oxypurines and ascorbate to prevent and mitigate iron-catalized oxidative damage in Alzheimer's disease and other neurodegenerative disorders

WAUGH WILLIAM HOWARD.

· 2007-11-27

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D.

Proc Natl Acad Sci U S A · 2007-11-27

DOI: 10.1073/pnas.0706006104PMID: 18042721

Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.

Steiger M.

Eur J Neurol · 2007-11-27

DOI: 10.1111/j.1468-1331.2007.01674.xPMID: 18042245

NOP RECEPTOR AGONISTS FOR THE TREATMENT OF L-DOPA INDUCED DYSKINESIAS

MORARI MICHELE, MARTI MATTEO.

· 2007-11-23

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.

Rasmussen VG, Poulsen SH, Dupont E, Østergaard K, Safikhany G, Egeblad H.

J Intern Med · 2007-11-23

DOI: 10.1111/j.1365-2796.2007.01874.xPMID: 18036161

THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES

GRIFFIOEN GERARD, WERA STEFAAN, DUHAMEL HEIN ROGER, VAN DAMME NIELE, GOMME ELLEN.

· 2007-11-22

THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES

GRIFFIOEN GERARD, WERA STEFAAN, DUHAMEL HEIN ROGER, GOMME ELLEN, VAN DAMME NELE.

· 2007-11-22

From bench to bed: the potential of stem cells for the treatment of Parkinson's disease.

Morizane A, Li JY, Brundin P.

Cell Tissue Res · 2007-11-22

DOI: 10.1007/s00441-007-0541-0PMID: 18034267

METAL DELIVERY AGENTS AND THERAPEUTIC USES OF THE SAME

BARNHAM KEVIN JEFFREY, DONNELLY PAUL STEPHEN, WHITE ANTHONY ROBERT.

· 2007-11-20

Differences between normal and alpha-synuclein overexpressing SH-SY5Y neuroblastoma cells after Abeta(1-42) and NAC treatment.

Hunya A, Földi I, Szegedi V, Soós K, Zarándi M, Szabó A, Zádori D, Penke B, Datki ZL.

Brain Res Bull · 2007-11-20

DOI: 10.1016/j.brainresbull.2007.10.035PMID: 18355641

Functional balance performance in patients with Parkinson's disease after long-term treatment with subthalamic nucleus high-frequency stimulation.

Nilsson MH, Jarnlo GB, Rehncrona S.

Parkinsonism Relat Disord · 2007-11-19

DOI: 10.1016/j.parkreldis.2007.09.003PMID: 18024162